ClinicalTrials.gg
RecruitingNCT07158749Updated Oct 13, 2026

Generalized and Domain-Specific Episodic Thinking for Smoking Cessation

An interventional study of Episodic Future Thinking (EFT) and Episodic Recent Thinking (ERT) in Cigarette Smoking Behavior, sponsored by Virginia Polytechnic Institute and State University. Recruiting at 1 site in United States. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Virginia Polytechnic Institute and State University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 1 month later.
Updated Oct 13, 2026Now RecruitingSite recruiting status changed+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
134
Allocation
Randomized
Ages
21 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 15 studies in Cigarette Smoking by Virginia Polytechnic Institute and State University — 3 open to participants now, 3 under way, none of them phase 3. Cigarette Smoking · Virginia Polytechnic Institute and State University.

Planned enrollment
6th of 15
134 · median 87
Started
2026
with 1 other
No phase
14 of 15
3 open now
Registered
14th of 15
by date

Among the 15 studies in Cigarette Smoking by Virginia Polytechnic Institute and State University, this one is the 6th largest by planned enrollment, is one of 2 that started in 2026, is one of 14 with no phase, and was the 14th registered.

Cigarette Smoking

477 studies on the registry are indexed under Cigarette Smoking; 87 are open to participants now.

Browse Cigarette Smoking studies →

Open to participants now

3 of the 15 studies in Cigarette Smoking by Virginia Polytechnic Institute and State University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 62 Cigarette Smoking studies recruiting now, 38 (61%) set no upper age limit and 18 (29%) stop at 75 or younger; 1 takes children under 18; 33 take healthy volunteers.

This study: 21 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Cigarette Smoking by Virginia Polytechnic Institute and State University, or all of them as a file.
02

Study summary

Cigarette smoking remains common, particularly in rural areas, despite ample evidence that smoking causes cancer and respiratory disease. Successful smoking cessation yields the majority of its health benefits (e.g., avoidance of lung cancer) after years of sustained behavioral change; however, people who smoke cigarettes tend to show elevated rates of delay discounting (i.e., devaluation of delayed outcomes) and a bias for immediate gratification. The overall goal of this project is to develop different versions of an episodic future thinking intervention (i.e., visualization of the future) and test their feasibility and efficacy for smoking cessation in rural and urban populations.

Read the detailed description

Cigarette smoking causes more than a dozen cancers, including cancers of the head and neck, colon, bladder, and lung. Although quitting smoking drastically reduces the risk of cancer mortality, rates of cessation are low, particularly in rural areas and other communities. Current evidence-based treatments for smoking cessation have made progress, but substantial room for innovation remains and novel strategies are needed. Successful smoking cessation may be considered, in part, an intertemporal choice between continuing to smoke and achieving the delayed health benefits associated with quitting (e.g., avoidance of lung cancer). Thus, quitting requires one's behavior to be sufficiently motivated by future outcomes. Unfortunately, robust cross-sectional and longitudinal evidence indicates that people who smoke cigarettes show elevated delay discounting, or a bias for immediate gratification. Prior research shows that delay discounting predicts treatment failure and relapse in smoking cessation. These findings suggest that delay discounting often prevents successful quitting because the health benefits of cessation (e.g., avoiding cancer) are too delayed to motivate sustained behavioral change. Thus, delay discounting is a therapeutic target in smoking cessation, where interventions that increase valuation of future outcomes may facilitate quitting. Episodic future thinking (EFT) is one such scalable intervention that is designed to shift time perspective and reduce bias for immediate gratification by promoting vivid and frequent visualization of a broad range of personally significant future events (e.g., weddings, birthdays, spending time with loved ones). In laboratory studies, research has shown that this form of generalized EFT in cigarette smokers reduces delay discounting and motivation to smoke (i.e., cigarette consumption, craving, and valuation). Moreover, strong preliminary evidence suggests that cancer-related EFT, a novel form of the intervention that involves visualizing the future experience of smoking-related lung cancer, may be more efficacious for reducing urges to smoke than the generalized form. The proposed trial will adapt both forms of EFT (generalized and cancer-related) for clinical use in smoking cessation. Remote intervention delivery and outcomes assessment (breath carbon monoxide and number of cigarettes smoked per day) will be used to minimize clinical burden and increase intervention reach and access, including in rural populations who often lack access to evidence-based treatments for smoking cessation. In an eight-week proof-of-concept trial, participants will be prompted to engage in EFT or control episodic thinking multiple times per day and during acute craving episodes. Specific Aims 1 and 2 will examine the feasibility and efficacy, respectively, of generalized and cancer-related EFT to reduce smoking. An Exploratory Aim will investigate the potential moderating role of income, education, sex, and other characteristics (e.g., baseline delay discounting, cigarettes/day) in the effects of EFT on smoking outcomes.

03

Conditions studied

  • Cigarette Smoking Behavior

Browse trials for

Keywords

  • Cigarette smoking
  • episodic future thinking
04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • smoked cigarettes daily for the last 30 days;
  • salivary cotinine > 30 ng/mL, consistent with tobacco use;
  • plan to quit smoking in the next 30 days

Exclusion criteria

Exclusion Criteria:

  • prior diagnosis with a smoking-related illness (e.g., respiratory disease);
  • past 30-day use any smoking cessation treatment;
  • anxiety or mood disorders; and
  • medical for use of nicotine replacement therapy (e.g. pregnancy).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Single (Outcomes assessor)
Enrollment
134 participants (estimated)

Study arms

  • Experimental
    Generalized episodic future thinking (EFT)

    The Generalized EFT group will identify positive events that may occur at 6 future time points (1 month to 5 years). These may include a broad range of personally significant milestones (e.g., weddings, birthdays) or other events that participants are looking forward to (e.g., spending time with loved ones). Participants will also generate vivid text descriptions, or cues (transcribed in their own words), to prompt EFT in the natural environment. These cues, including emotional impacts, will be elicited using standardized questions: Who are you with? What are you doing? Where are you? How are you feeling? Participants will be prompted to engage in Generalized EFT in the natural environment.

    Behavioral: Episodic Future Thinking (EFT) · Behavioral: Generalized episodic thinking

  • Experimental
    Domain-specific episodic future thinking (EFT)

    The Domain-Specific EFT group will complete an identical interview as the Generalized EFT group to identify positive future events, with one exception. Following initial cue generation, participants will be provided with descriptions of lung cancer symptoms (e.g., painful breathing; extreme fatigue; coughing up blood, phlegm, or mucus) and will be asked to visualize and include details related to this experience and their emotional impact in their revised cues. Thus, cancer-related symptoms occur in the context of otherwise positive, personally significant events to further highlight the impact of the diagnosis and to be consistent with Generalized EFT. Participants will be prompted to engage in Domain-Specific EFT in the natural environment.

    Behavioral: Episodic Future Thinking (EFT) · Behavioral: Domain-specific episodic thinking

  • Placebo comparator
    Generalized episodic recent thinking (ERT)

    The Generalized ERT interview will be identical to the one described for Generalized EFT, except participants will describe positive events they experienced in the last week. Participants will be prompted to engage in Generalized ERT in the natural environment.

    Behavioral: Episodic Recent Thinking (ERT) · Behavioral: Generalized episodic thinking

  • Active comparator
    Domain-specific episodic recent thinking (ERT)

    The Domain-Specific ERT interview will be identical to the one described for Domain-Specific EFT, except participants will describe positive events they experienced in the last week and will subsequently add detail as though they were experiencing symptoms of lung cancer. Participants will be prompted to engage in Domain-Specific ERT in the natural environment.

    Behavioral: Episodic Recent Thinking (ERT) · Behavioral: Domain-specific episodic thinking

Interventions

  • BehavioralEpisodic Future Thinking (EFT)

    Participants will engage in EFT for 8 weeks, three times a day. Participants will receive three daily text messages. Each prompt will link to a custom web interface that guides participants to read and vividly imagine one of their cues, chosen randomly. Visit times and durations will be recorded.

  • BehavioralEpisodic Recent Thinking (ERT)

    Participants will engage in ERT for 8 weeks, three times a day. Participants will receive three daily text messages. Each prompt will link to a custom web interface that guides participants to read and vividly imagine one of their cues, chosen randomly. Visit times and durations will be recorded.

  • BehavioralDomain-specific episodic thinking

    Content of the episodic thinking intervention will experiencing the symptoms of lung cancer during a broad range of personally meaningful, otherwise positive, events (e.g., social events, celebrations, spending times with friends and family).

  • BehavioralGeneralized episodic thinking

    Content of the episodic thinking intervention will include a broad range of personally meaningful, positive, events (e.g., social events, celebrations, spending times with friends and family).

06

What researchers measure

Primary outcomes

  1. Cigarettes smoked per day

    A timeline followback questionnaire will be used to assess the number of cigarettes smoked per day. Lower values reflect better outcomes.

    Time frame: From Week 0 to the end of treatment at 8 weeks

Secondary outcomes

  1. Other tobacco/nicotine product use per day

    A timeline followback questionnaire will be used to assess the number of times participants use other tobacco/nicotine products per day (excluding cigarettes and nicotine patch). Lower values reflect better outcomes.

    Time frame: From Week 0 to the end of treatment at 8 weeks

  2. 7-day point prevalence cigarette abstinence

    A timeline followback questionnaire will be used to assess cigarette abstinence status (binary) over the final seven days of the intervention.

    Time frame: Week 8

Other outcomes

  1. Nicotine patch adherence (feasibility outcome)

    A timeline followback questionnaire will be used to assess frequency of use of the study-provided nicotine patches. Higher values reflect better adherence to nicotine replacement therapy.

    Time frame: From Week 1 to the end of treatment at 8 weeks

  2. Depressive symptoms (feasibility outcome)

    Depression symptoms over the last 2 weeks will be assessed using the Patient Health Questionnaire-8 (PHQ-8). Total scores on this scale range from 0 (no depressive symptoms) to 24 (severe depressive symptoms).

    Time frame: From Week 0 to the end of treatment at 8 weeks

  3. Anxiety symptoms (feasibility outcome)

    Anxiety symptoms over the last 2 weeks will be assessed using the Generalized Anxiety Disorder-7 (GAD-7) questionnaire. Total scores on this scale range from 0 (no anxiety symptoms) to 21 (severe anxiety symptoms).

    Time frame: From Week 0 to the end of treatment at 8 weeks

  4. Episodic thinking adherence (feasibility outcome)

    Adherence to the episodic thinking interventions will be measured as the percentage of daily cue prompts that participants access.

    Time frame: From Week 1 to the end of treatment at 8 weeks

  5. Perceived convenience (feasibility outcome)

    Participants will evaluate perceived convenience of the intervention, both overall and its individual components, using visual analog scales with ratings ranging from 0 to 100. Higher ratings reflect greater convenience

    Time frame: From Week 1 to the end of treatment at 8 weeks

  6. Perceived helpfulness (feasibility outcome)

    Participants will evaluate perceived helpfulness of the intervention, both overall and its individual components, using visual analog scales with ratings ranging from 0 to 100. Higher ratings reflect greater helpfulness.

    Time frame: From Week 1 to the end of treatment at 8 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — All de-identified study data that are included in publication results will be shared using a project-specific url.

Supporting information: Statistical analysis plan, Informed consent form, Analytic code

Time frame: Study data and supporting information will be available beginning 3 months and ending 5 years after the publication of results.

Access criteria: All shared deidentified study data and supporting information will be available without restriction via a project-specific url.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Jun 2027, 9 months after the start.

Of 185 non-industry interventional studies with no phase under Cigarette Smoking, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 33. This study's planned 9 months is below that.

Counting every sponsor, half of 192 studies reached it within 20 months; a quarter within 8 and three quarters within 32.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 13, 2026: primary completion May 2027 → Jun 2027 and completion May 2027 → Jun 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 20, 2025
First posted
Sep 8, 2025
StartActual
Sep 25, 2026
Primary completionEst.
Jun 2027was May 2027
CompletionEst.
Jun 2027was May 2027
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 13, 2026
Sites
Fralin Biomedical Research Institute at VTC is now Recruiting
Oct 13, 2026
Start date
Sep 1, 2026→Sep 25, 2026 (actual)
Oct 13, 2026
Primary completion
May 1, 2027→Jun 2027
Oct 13, 2026
Study completion
May 1, 2027→Jun 2027
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Not yet recruiting→Recruiting
    Fralin Biomedical Research Institute at VTC is now Recruiting
    Start date Sep 1, 2026→Sep 25, 2026 (now actual)
    Primary completion May 1, 2027→Jun 2027
    Study completion May 1, 2027→Jun 2027
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07158749
Collaborators
National Cancer Institute (NCI), Roswell Park Comprehensive Cancer Center
Responsible party
Jeffrey Stein (Assistant Professor, Virginia Polytechnic Institute and State University) — Principal investigator
First posted
Sep 8, 2025
Start date
Sep 25, 2026
Primary completion
Jun 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Oct 13, 2026

Study contacts

Jeffrey Stein, PhD
Contact
jstein1@vtc.vt.edu
15405262124
Jeffrey Stein, PhD
principal investigator · Virginia Polytechnic Institute and State University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion